Novartis Investigative Site

Brandon, Florida 33511

0 studies enrolling now · 8 studies all time

What they study most

Acute Myocardial Infarction, Ankylosing Spondylitis, Asthma, Cardiovascular Disease and Lipoprotein(a), Chronic Obstructive Pulmonary Disease, Non Familial Chylocmicronemia Syndrome (Non-FCS), Psoriatic Arthritis

Studies at this site

• Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD — Running, not enrolling
• Prospective ARNI vs ACE Inhibitor Trial to DetermIne Superiority in Reducing Heart Failure Events After MI — Completed
• Study Estimating the Clinical Difference Between 300 mg and 150 mg of Secukinumab Following Dose Escalation to 300 mg in Patients With Ankylosing Spondylitis — Completed
• Lipoprotein(a) in Patients With Cardiovascular Disease (CVD) — Completed
• A Pilot Study to Assess the Efficacy and Safety of LCQ908 Alone and in Combination With Fenofibrate or Lovaza® in Patients With Severe Hypertriglyceridemia — Completed
• Study of Efficacy and Safety of QAW039 in Patients With Severe Asthma Inadequately Controlled With Standard of Care Asthma Treatment. — Completed
• Study to Demonstrate the Efficacy (Including Inhibition of Structural Damage), Safety and Tolerability up to 2 Years of Secukinumab in Active Psoriatic Arthritis — Completed
• NVA237 Versus Placebo 12-week Efficacy Study — Completed